A prospective, multi‐centre, Veterinary Radiation Therapy Oncology Group study reveals potential efficacy of toceranib phosphate (Palladia) as a primary or adjuvant agent in the treatment of canine nasal carcinoma.
Saved in:
| Title: | A prospective, multi‐centre, Veterinary Radiation Therapy Oncology Group study reveals potential efficacy of toceranib phosphate (Palladia) as a primary or adjuvant agent in the treatment of canine nasal carcinoma. |
|---|---|
| Authors: | Ehling, Tara Jean1,2 (AUTHOR) ehlingt@missouri.edu, Klein, Mary Kay2 (AUTHOR), Smith, Lauren2 (AUTHOR), Prescott, Deborah3 (AUTHOR), Haney, Siobhan4 (AUTHOR), Looper, Jayme5 (AUTHOR), LaDue, Tracey6 (AUTHOR), Brawner, William7 (AUTHOR), Fidel, Janean8 (AUTHOR), Shiomitsu, Keijiro9 (AUTHOR), Green, Eric10 (AUTHOR), Saba, Corey11 (AUTHOR), Turek, Michelle11 (AUTHOR), Farrelly, John12 (AUTHOR) |
| Source: | Veterinary & Comparative Oncology. Mar2022, Vol. 20 Issue 1, p293-303. 11p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
